Combined inactivation of MYC and K-ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Tran, Phuoc T ^a   Fan, Alice C ^a   Bendapudi, Pavan K ^a   Koh, Shan ^a   Komatsubara, Kim ^a   Chen, Joy ^a   Horng, George ^a   Bellovin, David I ^a   Giuriato, Sylvie ^b,c   Wang, Craig S ^a   Whitsett, Jeffrey A ^d   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MYC PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; ANTINEOPLASTIC AGENT; DOXYCYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE INACTIVATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; ONCOGENE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR REGRESSION; ADENOCARCINOMA; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUMOR; ONCOGENE MYC; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, MYC; GENES, RAS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MICE; MICE, TRANSGENIC; RESPIRATORY MUCOSA;

EID: 47749121455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002125     Document Type: Article

References (67)

1. Hahn WC, Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
2. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, et al. (1987) Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465-475.
3. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, et al. (2006) The c-Myc target gene network. Semin Cancer Biol 16: 253-264.
4. Arvanitis C, Felsher DW (2006) Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16: 313-317.
5. Bachireddy P, Bendapudi PK, Felsher DW (2005) Getting at MYC through RAS. Clin Cancer Res 11: 4278-4281.
6. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
7. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, et al. (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6: 308-318.
8. Greaves MF (1986) Differentiation-linked leukemogenesis in lymphocytes. Science 234: 697-704.
9. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P (1986) Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 45: 485-495.
10. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
11. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW (2004) Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 14: 3-11.
12. Weinstein IB (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
13. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, et al. (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
14. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104.
15. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mot Cell 4: 199-207.
16. Jang JW, Boxer RB, Chodosh LA (2006) Isoform-specific Ras Activation and Oncogene Dependence in MYC and Wnt-induced Mammary Tumorigenesis. Mol Cell Biol.
17. Boxer RB, Jang JW, Sintasath L, Chodosh LA (2004) Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6: 577-586.
18. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, et al. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 17: 488-501.
19. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, et al. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451-461.
20. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath I, et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239.
21. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334.
22. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565-577.
23. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
24. Chin L, Tam A, Pomerantz J, Wong M, Holash J, et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
25. Ji H, Li D, Chen I, Shimamura T, Kobayashi S, et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
26. Ji H, Zhao Y, Yuza Y, Shimamura T, Li D, et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103: 7817-7822.
27. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
28. Regales L, Balak MN, Gong Y, Politi K, Sawai A, et al. (2007) Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2: e810.
29. Ji H, Wang Z, Perera SA, Li D, Liang MC, et al. (2007) Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939.
30. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, et al. (2007) Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell 12: 81-93.
31. Sawyers C (2004) Targeted cancer therapy. Nature 432: 294-297.
32. Weinstein IB, Joe AK (2006) Mechanism of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
33. Milton DT, Riely GJ, Pao W, Miller VA, Kris MG, et al. (2006) Molecular on/off switch. J Clin Oncal 24. 4940-4942.
34. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up ofpatients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
35. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042.
36. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
37. Arteaga CL (2007) HER3 and mutant EGFR meet MET. Nat Med 13: 675-677.
38. Stommel JM, Kimmelman AC, Ying H, Nabioullin It, Ponugoti AH, et al. (2007) Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science 318: 287-290.
39. Perl AK, Tichelaar JW, Whitsett JA (2002) Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res 11: 21-29.
40. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, et al. (2004) Classification of Proliferative Pulmonary Lesions of the Mouse: Recommendations of the Mouse Models of Human Cancers Consortium. Cancer Res 64: 2307-2316.
41. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
42. Sharma SV, Fischbach MA, Haber DA, Settleman J (2006) "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12: 4392s-4395s.
43. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
44. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, et al. (2007) Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 117: 314-325.
45. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, et al. (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16: 2045-2057.
46. Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381-392.
47. Repaaky GA, Chenette EJ, Der CJ (2004) Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14: 639-647.
48. Sun S, Steinberg BM (2002) PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 83: 1651-1658.
49. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA (2006) Signal transducer and activator of transcriptioa 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168.
50. Haura EB, Zheng Z, Song L, Cantor A, Bepler G (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294.
51. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
52. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698.
53. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, et al. (2005) Somatic mutations of die HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
54. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003.
55. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in huma lung cancer. Cancer Res 65: 7591-7595.
56. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000.
57. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
58. Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, et al. (2006) EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184.
59. Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, et al. (2006) Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206.
60. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, et al. (2006) ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett 237: 89-94.
61. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2: e426.
62. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856.
63. Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241.
64. Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
65. Wittig I, Groner B (2005) Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells. Curr Drug Targets Immune Endocr Metabol Disord 5: 449-463.
66. Fritsca TMEF, Sambrook J, eds (1982) Molecular Cloning.: Cold Spring Harbor Laboratory, Cold Spring Harbor.
67. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, et al. (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31: 1116-1128.